Table 1. Summary of demographic, clinical and laboratory data of study groups.
| Participant characteristics | Patients with active TB | HIV -ve healthy volunteers | ||||||
|---|---|---|---|---|---|---|---|---|
| TST | Saline controls | |||||||
| HIV -ve | HIV +ve | HIV -ve | HIV +ve | TST -ve | ||||
| TST -ve | TST +ve | TB-IRIS | ||||||
| Number | 16 | 14 | 9 | 3 | 3 | 5 | 5 | |
| Age (median & range) | 38 (25–71) | 36.5 (26–58) | 40 (23–64) | 37 (19–50) | 45 (29–54) | 39 (30–53) | 36 (22–44) | |
| Gender | Male (%) | 62.50 | 50 | 33.33 | 0 | 66.67 | 60 | 40 |
| Female (%) | 37.50 | 50 | 66.67 | 100 | 33.33 | 40 | 60 | |
| Ethnicity | White (%) | 12.50 | 0 | 0 | 0 | 0 | 0 | 20 |
| Black (%) | 62.50 | 92.86 | 100 | 100 | 66.67 | 80 | 0 | |
| Mixed (%) | 0 | 7.14 | 0 | 0 | 33.33 | 20 | 80 | |
| Asian (%) | 25 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Site of disease | Pulmonary (%) | 56.25 | 71.43 | 100 | 100 | 100 | 80 | N/A |
| Extra-pulmonary (%) | 43.75 | 28.57 | 0 | 0 | 0 | 20 | ||
| MDR TB (%) | 12.50 | 0 | 0 | 0 | 0 | 0 | N/A | |
| TB treatment days at TST (median & range) | 11.5 (1–32) | 9 (1–28) | 15 (2–28) | 10 (3–13) | 4 (3–4) | 2 (1–13) | N/A | |
| CD4 count (cells/μL, median & range) | N/A | 28 (2–207) | 214 (34–511) | 279 (128–507) | N/A | 105 (46–412) | N/A | |
| Log10 HIV-1 copies/mL (median & range) | N/A | 5.3 (2.1–6.3) | 5.2 (1.7–6.0) | 1.8 (1.7–5.3) | N/A | 4.8 (1.7–5.9) | N/A | |
| ARV use (%) | N/A | 35.7 | 55.56 | 100 | N/A | 40.00 | N/A | |
| Weeks ART before TB (median & range) | N/A | 0.7 (0–24) | 123 (0–311) | 3.7 (2–6.6) | N/A | 2–6.6 | N/A | |
| mm induration (median & range) | 21 (12–28) | 0 | 16 (10–24) | 24 (21–26) | N/A | N/A | 0 | |